Molecular pathways: comparing the effects of drugs and T cells to effectively target oncogenes

Area of Science:

• Oncology
• Immunotherapy
• Cancer Therapeutics

Background:

• Mutant cancer oncogenes are key therapeutic targets for small-molecule inhibitors (SMI) and adoptive T-cell therapy (ATT).
• Oncogene-dependent cancer cells are challenging to target due to homogeneous expression and genetic instability, leading to therapy resistance.
• Both SMI and ATT show efficacy but share the risk of resistance.

Purpose of the Study:

• To compare the efficacy of SMI and ATT in a preclinical cancer model targeting the same oncogene.
• To elucidate the mechanisms behind tumor regression and relapse in response to different cancer therapies.
• To determine optimal conditions for translating ATT from experimental models to clinical application.

Main Methods:

• Comparative preclinical study of small-molecule inhibitors (SMI) and adoptive T-cell therapy (ATT) against a common oncogene target.
• Analysis of tumor response, including resistance mechanisms and tumor vasculature.
• Investigation of cellular and molecular mechanisms driving tumor regression and relapse.

Main Results:

• SMI treatment selected for resistant clones, resulting in tumor relapse.
• ATT completely eradicated large, established tumors, likely due to destruction of tumor vasculature.
• Differential mechanisms of tumor destruction explain the varied outcomes.

Conclusions:

• Adoptive T-cell therapy (ATT) demonstrates superior efficacy over SMI in eradicating established tumors by targeting tumor vasculature.
• Understanding the mechanisms of ATT-mediated regression and relapse is crucial for clinical optimization.
• The success of ATT in experimental models suggests potential for translation to human cancer patients.